TY - JOUR
T1 - Multicenter assessment of outcomes and complications associated with transforaminal versus anterior lumbar interbody fusion for fractional curve correction
AU - The International Spine Study Group
AU - Buell, Thomas J.
AU - Shaffrey, Christopher I.
AU - Bess, Shay
AU - Kim, Han Jo
AU - Klineberg, Eric O.
AU - Lafage, Virginie
AU - Lafage, Renaud
AU - Protopsaltis, Themistocles S.
AU - Passias, Peter G.
AU - Mundis, Gregory M.
AU - Eastlack, Robert K.
AU - Deviren, Vedat
AU - Kelly, Michael P.
AU - Daniels, Alan H.
AU - Gum, Jeffrey L.
AU - Soroceanu, Alex
AU - Hamilton, D. Kojo
AU - Gupta, Munish C.
AU - Burton, Douglas C.
AU - Hostin, Richard A.
AU - Kebaish, Khaled M.
AU - Hart, Robert A.
AU - Schwab, Frank J.
AU - Ames, Christopher P.
AU - Smith, Justin S.
N1 - Funding Information:
The International Spine Study Group is funded through research grants from DePuy Synthes. Dr. Shaffrey is a consultant for Medtronic, NuVasive, SI Bone; owns stock in NuVasive; holds patents with Medtronic, NuVasive, and Zimmer Biomet; and receives royalties from Medtronic and NuVasive. Dr. Bess is a consultant for K2M Stryker; owns stock in Carlsmed Progenerative Medicine; receives clinical or research support for the study described from NuVasive, K2M, Stryker, and DePuy Synthes; holds patents with K2M Stryker; and receives support for non–study-related clinical or research effort from Medtronic, Globus, SI Bone, and Sea-Spine. Dr. Klineberg is a consultant for DePuy Synthes, Stryker, and Medicrea/Medtronic; receives honoraria from AO Spine; and receives grants from AO Spine for Fellowship Education. Dr. Laf-age is a consultant for Globus Medical; receives royalties from NuVasive; receives honoraria from The Permanente Group, DePuy Synthes, and Implanet; and owns stock in Nemaris Inc. Mr. Laf-age owns stock in Nemaris. Dr. Protopsaltis is a consultant for Globus, NuVasive, Medtronic, Medicrea, and Stryker K2; receives royalties from Altus; and owns stock options in SpineAlign and Torus. Dr. Passias is a consultant for Medicrea, Royal Biologics, SpineWave, and Terumo; serves on the speakers bureau of Zimmer and Globus Medical; and receives support for non–study-related clinical or research effort from cSRS and AlloSource. Dr. Mundis is a consultant for NuVasive, Carlsmed, SeaSpine, and Viseon; and owns stock in NuVasive, Carlsmed, and Viseon. Dr. Eastlack is a consultant for Spinal Elements, Carevature, Aesculap, NuVa- sive, SeaSpine, SI Bone, Stryker, and Medtronic; owns stock in NuVasive, Alphatec, SeaSpine, and Spine Innovation; holds patents with Spine Innovation, Globus, and Stryker; receives clinical or research support for the study described from NuVasive, SeaSpine, and Medtronic; serves on the speakers bureau of Radius; and receives royalties from Globus, NuVasive, SI Bone, and Aesculap. Dr. Kelly receives honoraria from The Journal of Bone and Joint Surgery; and receives support for non–study-related clinical or research effort from ISSGF/SSSF. Dr. Daniels is a consultant for Stryker, Spineart, Orthofix, Southern Spine, and Medicrea. Dr. Gum is an employee of Norton Healthcare; is a consultant for Medtronic, Acuity, K2M/Stryker, NuVasive, and Mazor; serves on the speakers bureau of DePuy Synthes; receives royalties from Acuity and NuVasive; receives honoraria from Pacira Pharmaceutical, Baxter, Broadwater, and NASS; receives clinical or research support for the study described from Integra, Intellirod Spine Inc., Pfizer, International Spine Study Group, NuVasive, and Norton Healthcare; owns stock in Cingulate Therapeutics; holds patents with Medtronic; and serves on the advisory/editorial boards of K2M/Stryker, Medtronic, and National Spine Health. Dr. Gupta is a consultant for DePuy Synthes and Medtronic; receives royalties from DePuy Synthes, Innomed, and Globus; owns stock in J&J and P&G; receives travel expenses from Globus, Medtronic, DePuy Synthes, Medicrea, Mizuho, and the Scoliosis Research Society; and receives travel expenses and honoraria from AO Spine. Dr. Burton owns stock in Progenerative Medical; receives clinical or research support for the study described from DePuy Synthes; and receives royalties from DePuy Synthes. Dr. Schwab is a consultant for Globus Medical, MSD, and Zimmer Biomet; owns stock in VFT Solutions; receives royalties from MSD and Zimmer Biomet; and serves on the executive committee of the International Spine Study Group. Dr. Ames is an employee of UCSF; is a consultant for Medicrea, DePuy Synthes, Medtronic, and Medicrea; receives royalties from Zimmer Biomet, DePuy Synthes, NuVasive, Next Orthosurgical, and K2M; receives research support from K2M, Titan Spine, DePuy Synthes, and ISSG; serves on the editorial board of Operative Neurosurgery; receives grant funding from SRS; serves on the executive committee of ISSG; and serves as the director of Global Spinal Analytics. Dr. Smith is a consultant for Zimmer Biomet, NuVasive, Stryker, DePuy Synthes, Cerapedics, and Carlsmed; receives royalties from Zimmer Biomet, NuVa-sive, and Thieme; owns stock in Alphatec and NuVasive; receives clinical or research support for the study described from DePuy Synthes and ISSGF; receives non–study-related clinical or research effort from DePuy Synthes, ISSGF, NuVasive, and AO Spine; and received fellowship support from AO Spine.
Publisher Copyright:
© AANS 2021, except where prohibited by US copyright law.
PY - 2021/12
Y1 - 2021/12
N2 - OBJECTIVE Few studies have compared fractional curve correction after long fusion between transforaminal lumbar interbody fusion (TLIF) and anterior lumbar interbody fusion (ALIF) for adult symptomatic thoracolumbar/lumbar scoliosis (ASLS). The objective of this study was to compare fractional correction, health-related quality of life (HRQL), and complications associated with L4–S1 TLIF versus those of ALIF as an operative treatment of ASLS. METHODS The authors retrospectively analyzed a prospective multicenter adult spinal deformity database. Inclusion required a fractional curve ≥ 10°, a thoracolumbar/lumbar curve ≥ 30°, index TLIF or ALIF performed at L4–5 and/or L5–S1, and a minimum 2-year follow-up. TLIF and ALIF patients were propensity matched according to the number and type of interbody fusion at L4–S1. RESULTS Of 135 potentially eligible consecutive patients, 106 (78.5%) achieved the minimum 2-year follow-up (mean ± SD age 60.6 ± 9.3 years, 85% women, 44.3% underwent TLIF, and 55.7% underwent ALIF). Index operations had mean ± SD 12.2 ± 3.6 posterior levels, 86.6% of patients underwent iliac fixation, 67.0% underwent TLIF/ALIF at L4–5, and 84.0% underwent TLIF/ALIF at L5–S1. Compared with TLIF patients, ALIF patients had greater cage height (10.9 ± 2.1 mm for TLIF patients vs 14.5 ± 3.0 mm for ALIF patients, p = 0.001) and lordosis (6.3° ± 1.6° for TLIF patients vs 17.0° ± 9.9° for ALIF patients, p = 0.001) and longer operative duration (6.7 ± 1.5 hours for TLIF patients vs 8.9 ± 2.5 hours for ALIF patients, p < 0.001). In all patients, final alignment improved significantly in terms of the fractional curve (20.2° ± 7.0° to 6.9° ± 5.2°), maximum coronal Cobb angle (55.0° ± 14.8° to 23.9° ± 14.3°), C7 sagittal vertical axis (5.1 ± 6.2 cm to 2.3 ± 5.4 cm), pelvic tilt (24.6° ± 8.1° to 22.7° ± 9.5°), and lumbar lordosis (32.3° ± 18.8° to 51.4° ± 14.1°) (all p < 0.05). Matched analysis demonstrated comparable fractional correction (-13.6° ± 6.7° for TLIF patients vs -13.6° ± 8.1° for ALIF patients, p = 0.982). In all patients, final HRQL improved significantly in terms of Oswestry Disability Index (ODI) score (42.4 ± 16.3 to 24.2 ± 19.9), physical component summary (PCS) score of the 36-item Short-Form Health Survey (32.6 ± 9.3 to 41.3 ± 11.7), and Scoliosis Research Society–22r score (2.9 ± 0.6 to 3.7 ± 0.7) (all p < 0.05). Matched analysis demonstrated worse ODI (30.9 ± 21.1 for TLIF patients vs 17.9 ± 17.1 for ALIF patients, p = 0.017) and PCS (38.3 ± 12.0 for TLIF patients vs 45.3 ± 10.1 for ALIF patients, p = 0.020) scores for TLIF patients at the last follow-up (despite no differences in these parameters at baseline). The rates of total complications were similar (76.6% for TLIF patients vs 71.2% for ALIF patients, p = 0.530), but significantly more TLIF patients had rod fracture (28.6% of TLIF patients vs 7.1% of ALIF patients, p = 0.036). Multiple regression analysis demonstrated that a 1-mm increase in L4–5 TLIF cage height led to a 2.2° reduction in L4 coronal tilt (p = 0.011), and a 1° increase in L5–S1 ALIF cage lordosis led to a 0.4° increase in L5–S1 segmental lordosis (p = 0.045). CONCLUSIONS Operative treatment of ASLS with L4–S1 TLIF versus ALIF demonstrated comparable mean fractional curve correction (66.7% vs 64.8%), despite use of significantly larger, more lordotic ALIF cages. TLIF cage height had a significant impact on leveling L4 coronal tilt, whereas ALIF cage lordosis had a significant impact on restoration of lumbosacral lordosis. The advantages of TLIF may include reduced operative duration and hospitalization; however, associated HRQL was inferior and more rod fractures were detected in the TLIF patients included in this study.
AB - OBJECTIVE Few studies have compared fractional curve correction after long fusion between transforaminal lumbar interbody fusion (TLIF) and anterior lumbar interbody fusion (ALIF) for adult symptomatic thoracolumbar/lumbar scoliosis (ASLS). The objective of this study was to compare fractional correction, health-related quality of life (HRQL), and complications associated with L4–S1 TLIF versus those of ALIF as an operative treatment of ASLS. METHODS The authors retrospectively analyzed a prospective multicenter adult spinal deformity database. Inclusion required a fractional curve ≥ 10°, a thoracolumbar/lumbar curve ≥ 30°, index TLIF or ALIF performed at L4–5 and/or L5–S1, and a minimum 2-year follow-up. TLIF and ALIF patients were propensity matched according to the number and type of interbody fusion at L4–S1. RESULTS Of 135 potentially eligible consecutive patients, 106 (78.5%) achieved the minimum 2-year follow-up (mean ± SD age 60.6 ± 9.3 years, 85% women, 44.3% underwent TLIF, and 55.7% underwent ALIF). Index operations had mean ± SD 12.2 ± 3.6 posterior levels, 86.6% of patients underwent iliac fixation, 67.0% underwent TLIF/ALIF at L4–5, and 84.0% underwent TLIF/ALIF at L5–S1. Compared with TLIF patients, ALIF patients had greater cage height (10.9 ± 2.1 mm for TLIF patients vs 14.5 ± 3.0 mm for ALIF patients, p = 0.001) and lordosis (6.3° ± 1.6° for TLIF patients vs 17.0° ± 9.9° for ALIF patients, p = 0.001) and longer operative duration (6.7 ± 1.5 hours for TLIF patients vs 8.9 ± 2.5 hours for ALIF patients, p < 0.001). In all patients, final alignment improved significantly in terms of the fractional curve (20.2° ± 7.0° to 6.9° ± 5.2°), maximum coronal Cobb angle (55.0° ± 14.8° to 23.9° ± 14.3°), C7 sagittal vertical axis (5.1 ± 6.2 cm to 2.3 ± 5.4 cm), pelvic tilt (24.6° ± 8.1° to 22.7° ± 9.5°), and lumbar lordosis (32.3° ± 18.8° to 51.4° ± 14.1°) (all p < 0.05). Matched analysis demonstrated comparable fractional correction (-13.6° ± 6.7° for TLIF patients vs -13.6° ± 8.1° for ALIF patients, p = 0.982). In all patients, final HRQL improved significantly in terms of Oswestry Disability Index (ODI) score (42.4 ± 16.3 to 24.2 ± 19.9), physical component summary (PCS) score of the 36-item Short-Form Health Survey (32.6 ± 9.3 to 41.3 ± 11.7), and Scoliosis Research Society–22r score (2.9 ± 0.6 to 3.7 ± 0.7) (all p < 0.05). Matched analysis demonstrated worse ODI (30.9 ± 21.1 for TLIF patients vs 17.9 ± 17.1 for ALIF patients, p = 0.017) and PCS (38.3 ± 12.0 for TLIF patients vs 45.3 ± 10.1 for ALIF patients, p = 0.020) scores for TLIF patients at the last follow-up (despite no differences in these parameters at baseline). The rates of total complications were similar (76.6% for TLIF patients vs 71.2% for ALIF patients, p = 0.530), but significantly more TLIF patients had rod fracture (28.6% of TLIF patients vs 7.1% of ALIF patients, p = 0.036). Multiple regression analysis demonstrated that a 1-mm increase in L4–5 TLIF cage height led to a 2.2° reduction in L4 coronal tilt (p = 0.011), and a 1° increase in L5–S1 ALIF cage lordosis led to a 0.4° increase in L5–S1 segmental lordosis (p = 0.045). CONCLUSIONS Operative treatment of ASLS with L4–S1 TLIF versus ALIF demonstrated comparable mean fractional curve correction (66.7% vs 64.8%), despite use of significantly larger, more lordotic ALIF cages. TLIF cage height had a significant impact on leveling L4 coronal tilt, whereas ALIF cage lordosis had a significant impact on restoration of lumbosacral lordosis. The advantages of TLIF may include reduced operative duration and hospitalization; however, associated HRQL was inferior and more rod fractures were detected in the TLIF patients included in this study.
KW - Adult spinal deformity
KW - Anterior lumbar interbody fusion
KW - Complications
KW - Fractional curve
KW - Outcomes
KW - Scoliosis
KW - Transforaminal lumbar interbody fusion
UR - http://www.scopus.com/inward/record.url?scp=85126830513&partnerID=8YFLogxK
U2 - 10.3171/2020.11.SPINE201915
DO - 10.3171/2020.11.SPINE201915
M3 - Article
C2 - 34416723
AN - SCOPUS:85126830513
SN - 1547-5654
VL - 35
SP - 729
EP - 742
JO - Journal of Neurosurgery: Spine
JF - Journal of Neurosurgery: Spine
IS - 6
ER -